Conclusions
1 evidence topic · 16 sources
Summary
Obefazimod is an investigational “oral small molecule” for moderately to severely active ulcerative colitis. Abivax states that it “has not yet been approved for commercial use in any jurisdiction”, and no new drug application (NDA) has been submitted to the FDA. In the two 8-week, placebo-controlled induction trials, clinical remission at Week 8 (primary endpoint) with obefazimod 50 mg occurred in 21.7% against 2.5% with placebo in ABTECT-1 (difference 19.3%, p<0.0001) and in 19.8% against 6.3% in ABTECT-2 (difference 13.4%, p=0.0001); with 25 mg it occurred in 23.8% in ABTECT-1 (difference 21.4%, p<0.0001) and in 11.3% in ABTECT-2 (difference 5.1%, p=0.1034). In a pooled analysis with nominal p-values, clinical remission with 50 mg occurred in 13.3% against 3.4% with placebo among participants with a prior inadequate response to advanced therapy and in 27.7% against 5.3% among those without. In ABTECT Maintenance, among 580 obefazimod induction responders re-randomized for 44 weeks, clinical remission at Week 44 (primary endpoint) occurred in 50.8% with 25 mg and 51.3% with 50 mg against 10.4% with placebo (p<0.0001). Headache was the most frequent treatment-emergent adverse event in the induction trials (20.8% to 25.8% with 50 mg, 14.5% to 15.6% with 25 mg, and 5.7% with placebo).
No peer-reviewed full publication of any ABTECT trial exists as of November 2026; the results come from congress abstracts and presentations, company press releases and filings, and the posted registry results of the induction trials, and the ClinicalTrials.gov record of the maintenance trial shows “No Results Posted”. Each phase 3 trial compared obefazimod with placebo, and no trial comparing obefazimod with another advanced therapy was identified. In Part 1 of ABTECT Maintenance, malignancies other than non-melanoma skin cancer (NMSC) occurred only with 50 mg, one prostate cancer, one breast cancer, and one colonic dysplasia, which the company release calls the “prostate, breast, and colon cancer cases”; NMSC occurred in 1 participant with placebo, 1 with 25 mg, and “four 50 mg patients”. Part 2, which has no placebo group, reported “two non-NMSC malignancies” with 50 mg and four NMSC events, and the investigator determined one basal cell carcinoma (50 mg) and one squamous cell carcinoma (25 mg) “probably related to study drug”. In the company's “integrated post-hoc analyses”, the exposure-adjusted incidence in the phase 3 maintenance dataset with 50 mg was 0.91 per 100 patient-years for malignancies excluding NMSC and 1.37 for NMSC, which the company sets beside expected ulcerative colitis background ranges of 0.30 to 0.70 and 0.70 to 1.40, and the company states that the rates of the combined active arms are “within the UC background reference range based on published UC studies”. Results of phase 1 studies are deferred in the EU register, to be published from 28 February 2027 (combined oral contraceptive interaction), 11 March 2027 (hepatic impairment), 20 August 2027 (rosuvastatin interaction), and 14 April 2028 (renal impairment).
Abivax states that it “remains on track to submit its first NDA for obefazimod by the end of 2026”. The outcome of FDA review, the approved indication, dose, and labeling, and the price are unknown. Obefazimod has no wholesale acquisition cost or average sales price; the one price figure identified is an analyst assumption by LifeSci Capital of a “net annual price at launch of US$78,000 in the U.S.” No budget impact model, cost-effectiveness analysis, or health technology assessment of obefazimod was identified.